Jason A. Okazaki Sells 1,569 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) CEO Jason A. Okazaki sold 1,569 shares of the business’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $12.71, for a total value of $19,941.99. Following the completion of the transaction, the chief executive officer now owns 16,423 shares of the company’s stock, valued at approximately $208,736.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Assembly Biosciences Stock Performance

ASMB stock opened at $12.81 on Friday. Assembly Biosciences, Inc. has a 1-year low of $7.69 and a 1-year high of $20.04. The business has a fifty day moving average price of $13.19 and a 200-day moving average price of $11.16.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ASMB. StockNews.com upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, April 5th. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research note on Monday, April 1st.

Institutional Trading of Assembly Biosciences

A hedge fund recently bought a new stake in Assembly Biosciences stock. Marquette Asset Management LLC acquired a new stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned about 0.08% of Assembly Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). 19.92% of the stock is owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.